Genprex Inc. has announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering the use of its lead drug candidate, Reqorsa® Gene Therapy, in combination with PD-L1 antibodies, such as Tecentriq®. Additionally, the European Patent Office has issued a Notice of Allowance for a patent covering the use of REQORSA in combination with PD-1 antibodies. Both patents will expire in 2037 at the earliest. These developments enhance Genprex's intellectual property estate for its oncology program involving immune checkpoint inhibitors, specifically applicable to the Acclaim-3 clinical trial. Furthermore, Genprex is pursuing additional patent applications in Europe, Canada, Brazil, China, and Israel, which, if granted, would also support the Acclaim-3 trial.